NCT05878314 2026-02-10
Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer
University Hospital Tuebingen
Recruiting
Clinical Trials
4 trialsNCT06705504 2024-11-26
A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib
Novartis
Completed
NCT05901428 2023-06-15
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Fudan University
Phase 3 Recruiting
NCT02692755 2021-09-28
PALINA
Georgetown University
Phase 2/3 Completed